France’s Gemme Claims A Victory With Price-Cut Reversal
Moratorium On Price Cuts Accompanies Targeted Increases To Address Shortages
French generics industry association Gemme has claimed a major victory in shifting the country’s policy on generic price cuts, after the government announced a moratorium on price reductions as well as targeted price increases for certain key locally-produced generics.
You may also be interested in...
Markus Sieger, vice-president of off-patent industry association Medicines for Europe and CEO of Polpharma, spoke to Generics Bulletin about critical issues affecting supply in Europe, including pricing, supply chains, and his enthusiasm for ESG.
With Olon investing significantly in its production capacity and technical capabilities, CEO Paolo Tubertini believes the API specialist is well-positioned to provide resilience within the European supply chain. However, the chief executive also told Generics Bulletin that this robustness needs to be valued by pricing mechanisms.
Responding to shortages of antibiotics seen around the world, the IGBA has insisted that the generics industry is working to address spikes in demand and has set out a series of recommendations to mitigate the situation. Meanwhile, US association the AAM has countered suggestions that supply issues are due to a “broken generic drug market.”